AU2019384074B2 - Methods for administering corticosteroids - Google Patents

Methods for administering corticosteroids Download PDF

Info

Publication number
AU2019384074B2
AU2019384074B2 AU2019384074A AU2019384074A AU2019384074B2 AU 2019384074 B2 AU2019384074 B2 AU 2019384074B2 AU 2019384074 A AU2019384074 A AU 2019384074A AU 2019384074 A AU2019384074 A AU 2019384074A AU 2019384074 B2 AU2019384074 B2 AU 2019384074B2
Authority
AU
Australia
Prior art keywords
corticosteroid
dose
administered
urinary
hsd1 inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019384074A
Other languages
English (en)
Other versions
AU2019384074A1 (en
Inventor
David A. Katz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sparrow Pharmaceuticals Inc
Original Assignee
Sparrow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sparrow Pharmaceuticals Inc filed Critical Sparrow Pharmaceuticals Inc
Publication of AU2019384074A1 publication Critical patent/AU2019384074A1/en
Application granted granted Critical
Publication of AU2019384074B2 publication Critical patent/AU2019384074B2/en
Priority to AU2025203033A priority Critical patent/AU2025203033A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019384074A 2018-11-20 2019-08-14 Methods for administering corticosteroids Active AU2019384074B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025203033A AU2025203033A1 (en) 2018-11-20 2025-04-30 Methods for administering corticosteroids

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769932P 2018-11-20 2018-11-20
US62/769,932 2018-11-20
PCT/US2019/046449 WO2020106337A1 (en) 2018-11-20 2019-08-14 Methods for administering corticosteroids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025203033A Division AU2025203033A1 (en) 2018-11-20 2025-04-30 Methods for administering corticosteroids

Publications (2)

Publication Number Publication Date
AU2019384074A1 AU2019384074A1 (en) 2021-06-03
AU2019384074B2 true AU2019384074B2 (en) 2025-04-10

Family

ID=70774135

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019384074A Active AU2019384074B2 (en) 2018-11-20 2019-08-14 Methods for administering corticosteroids
AU2025203033A Pending AU2025203033A1 (en) 2018-11-20 2025-04-30 Methods for administering corticosteroids

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025203033A Pending AU2025203033A1 (en) 2018-11-20 2025-04-30 Methods for administering corticosteroids

Country Status (10)

Country Link
US (2) US12220412B2 (enExample)
EP (1) EP3883578A4 (enExample)
JP (2) JP7472122B2 (enExample)
CN (1) CN113329754A (enExample)
AU (2) AU2019384074B2 (enExample)
BR (1) BR112021009653A2 (enExample)
CA (1) CA3120339A1 (enExample)
IL (2) IL283069B2 (enExample)
MX (2) MX2021005801A (enExample)
WO (1) WO2020106337A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022076398A1 (en) * 2020-10-07 2022-04-14 Surface Ophthalmics, Inc. Pharmaceutical kits and their use for treating dry eye disease
AU2019384074B2 (en) 2018-11-20 2025-04-10 Sparrow Pharmaceuticals, Inc. Methods for administering corticosteroids
JP2022516099A (ja) 2018-12-27 2022-02-24 サーフィス オフサルミクス，インコーポレイテッド 眼科用医薬組成物及び癌表面疾患の処置方法
CA3128954A1 (en) * 2019-02-08 2020-08-13 Sanofi Biotechnological optimization of microorganisms for the 1,2-dehydrogenation of steroids
US12310981B2 (en) 2021-05-10 2025-05-27 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
WO2023225507A1 (en) * 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess
CA3250533A1 (en) 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR TREATING EXCESS GLUCOCORTICOIDS
WO2025072521A1 (en) * 2023-09-27 2025-04-03 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid-mediated diseases
GB202408335D0 (en) 2024-06-11 2024-07-24 Astrazeneca Ab Therapies for wound treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094699A1 (en) * 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
WO2010121814A1 (en) * 2009-04-22 2010-10-28 Ontochem Gmbh Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907821A (en) 1974-11-20 1975-09-23 Upjohn Co 2-{8 3-{8 1-(DIMETHYLAMINO)CYCLOPROPYL{8 -4H-1,2,4-triazol-4-yl{8 {0 benzophenone
US4577020A (en) 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
IL84093A (en) 1986-10-09 1992-09-06 Ciba Geigy Ag Aralkyl-4h-1,2,4-triazole derivatives,their preparation and pharmaceutical compositions containing them
GB0101447D0 (en) 2001-01-19 2001-03-07 Univ Edinburgh Regulation of glucocorticoid concentration
GB0107383D0 (en) 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
AUPR878201A0 (en) 2001-11-09 2001-12-06 Fujisawa Pharmaceutical Co., Ltd. New compounds
US20030148987A1 (en) 2001-12-21 2003-08-07 Morris David J. Selective 11beta-HSD inhibitors and methods of use thereof
JP4368683B2 (ja) 2002-02-01 2009-11-18 メルク エンド カムパニー インコーポレーテッド 糖尿病、肥満症および脂質代謝異常の治療に有用な１１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１阻害剤
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
PL375256A1 (en) 2002-08-09 2005-11-28 Astra Zeneca Ab 1,2,4-oxadiazoles as modulators of metabotropic glutamate receptor-5
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
JP2006522747A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 縮合１，２，４−トリアゾールの薬学的使用
DE602004027171D1 (de) 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
WO2004089367A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
US8026264B2 (en) 2003-05-29 2011-09-27 Merck Sharp And Dohme Corp. Triazole derivatives as inhibitors of 11-β hydroxysteroid dehydrogenase-1
JP2007509959A (ja) 2003-10-28 2007-04-19 アムゲン インコーポレイティッド トリアゾール化合物およびそれに関連する使用法
JP2005170939A (ja) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
EA200600990A1 (ru) 2003-12-19 2006-10-27 Пфайзер Инк. Производные бензосульфониламинопиридин-2-ила и родственные соединения в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы 1 типа (11-бета-hsd-1) для лечения диабета и ожирения
US7507832B2 (en) 2003-12-22 2009-03-24 Eli Lilly And Company Triazole PPAR modulators
EP1732904B1 (en) 2004-03-29 2014-03-19 Merck Sharp & Dohme Corp. Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7880001B2 (en) * 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US8022225B2 (en) 2004-08-04 2011-09-20 Taisho Pharmaceutical Co., Ltd Triazole derivative
CA2580409C (en) 2004-09-16 2013-08-13 Astellas Pharma Inc. Triazole derivative or salt thereof
JP2008518903A (ja) 2004-11-02 2008-06-05 ファイザー・インク 置換および非置換アダマンチルアミドの新規化合物
WO2006068199A1 (ja) 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
WO2006080533A1 (ja) 2005-01-31 2006-08-03 Mochida Pharmaceutical Co., Ltd. ３－アミノ－１,２,４－トリアゾール誘導体
WO2006134481A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
ES2334518T3 (es) 2005-06-16 2010-03-11 Pfizer, Inc. Derivados de n-(piridin-2-il)-sulfonamida.
CN101198605A (zh) 2005-06-16 2008-06-11 辉瑞大药厂 N-(吡啶-2-基)-磺酰胺衍生物
JPWO2007007688A1 (ja) 2005-07-08 2009-01-29 持田製薬株式会社 ３，５−ジアミノ−１，２，４−トリアゾール誘導体
US7615569B2 (en) 2005-08-16 2009-11-10 Icagen, Inc. Inhibitors of ion channels
UY29796A1 (es) 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
BRPI0708782A2 (pt) 2006-03-16 2011-06-14 Astellas Pharma Inc derivado de triazol ou um sal deste
US20070224298A1 (en) 2006-03-23 2007-09-27 Talbott Shawn M Inhibiting 11(beta)-hsd1 with citrus flavonoids
US7435833B2 (en) 2006-04-07 2008-10-14 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
MX2011000179A (es) * 2008-07-03 2011-04-05 Astellas Pharma Inc Derivado de triazol o su sal.
US8871208B2 (en) 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
UA112418C2 (uk) 2010-09-07 2016-09-12 Астеллас Фарма Інк. Терапевтичний болезаспокійливий засіб
CA2866220A1 (en) * 2012-03-13 2013-09-19 Abbvie Inc. Method for selecting or identifying a subject for v1b antagonist therapy
CN113018300B (zh) * 2014-07-09 2025-11-25 爱普制药有限责任公司 用于治疗神经病症的方法
EA036757B1 (ru) 2015-04-07 2020-12-17 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции для комбинированной терапии
US10648506B2 (en) 2016-07-07 2020-05-12 Raul Mendoza Walking rig creeper interface
WO2018117063A1 (ja) 2016-12-20 2018-06-28 アステラス製薬株式会社 焦燥性興奮治療剤
AU2019384074B2 (en) 2018-11-20 2025-04-10 Sparrow Pharmaceuticals, Inc. Methods for administering corticosteroids
EP3821892A1 (en) 2019-11-12 2021-05-19 University of Leeds (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds
EP3878446A1 (en) 2020-03-09 2021-09-15 Universite De Geneve Hsd11b1 inhibitors for use in immunotherapy and uses thereof
WO2023225507A1 (en) 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess
CA3250533A1 (en) 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR TREATING EXCESS GLUCOCORTICOIDS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094699A1 (en) * 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
WO2010121814A1 (en) * 2009-04-22 2010-10-28 Ontochem Gmbh Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KATZ D A ET AL: "Peripheral and central nervous system inhibition of 11[beta]-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384", TRANSLATIONAL PSYCHIATRY, vol. 3, no. 8, 1 August 2013 (2013-08-01), pages e295 - e295 *
TETSUO KISO ET AL: "Analgesic effects of ASP3662, a novel 11[beta]-hydroxysteroid dehydrogenase 1 inhibitor, in rat models of neuropathic and dysfunctional pain", BRITISH JOURNAL OF PHARMACOLOGY, vol. 175, no. 19, (2018), pages 3784 - 3796 *

Also Published As

Publication number Publication date
IL283069B1 (en) 2025-05-01
AU2025203033A1 (en) 2025-05-22
CN113329754A (zh) 2021-08-31
US20210393622A1 (en) 2021-12-23
CA3120339A1 (en) 2020-05-28
BR112021009653A2 (pt) 2021-08-17
JP7472122B2 (ja) 2024-04-22
WO2020106337A1 (en) 2020-05-28
US20250205227A1 (en) 2025-06-26
JP2022507103A (ja) 2022-01-18
MX2021005801A (es) 2021-08-05
EP3883578A1 (en) 2021-09-29
US12220412B2 (en) 2025-02-11
MX2025002836A (es) 2025-04-02
IL283069B2 (en) 2025-09-01
IL319327A (en) 2025-05-01
JP2024098991A (ja) 2024-07-24
AU2019384074A1 (en) 2021-06-03
EP3883578A4 (en) 2022-07-27
IL283069A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
AU2019384074B2 (en) Methods for administering corticosteroids
AU2024227357A1 (en) Ganaxolone For Use In Treating Genetic Epileptic Disorders
CN112533611A (zh) 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
US20200113882A1 (en) Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions
CN107427502A (zh) 使用川地匹坦的治疗方法
EP4483955A2 (en) Methods of medical treatment with sur1-trpm4 channel inhibitors
JP2022031479A (ja) アルツハイマー病治療に関連するアミロイド関連画像異常の治療または予防方法
CN105358160A (zh) 亚硝酸盐的药物制剂及其用途
KR20200062241A (ko) 시포니모드의 투여 요법
RU2709509C1 (ru) Режим дозирования для лечения острых обострений воспалительных состояний
US11571412B2 (en) Thromboxane receptor antagonists in AERD/asthma
RS60365B1 (sr) Lečenje alopecije areate
Cao et al. Probable rivaroxaban-induced erythema multiforme in children: A case report
JP6420923B1 (ja) 医薬
Santosh et al. STUDY OF PHENYTOIN DRUG RELATED WITH PHARMACOVIGILANCE
EP4019016A1 (en) Methods of administering intravenous baclofen
Мелешко et al. Pharmacology: practical manual
JP2018531271A (ja) 静脈内バクロフェン及び治療方法
CN117580581A (zh) 用于治疗重度抑郁障碍和产后抑郁症的19-去甲c3,3-二取代的c21-n-吡唑基类固醇
PELTIER et al. 10 Overview of Pain
US Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate
MXPA06004020A (en) Pharmaceutical composition comprising an analgesic and vitamins

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)